logo
Plus   Neg
Share
Email

Stock Alert: Genprex Hits New 52-week High

Shares of Genprex Inc. (GNPX) touched a new 52-week high in the morning trade on Friday, at $5.75. The stock has been rising since Tuesday and has traded in a range of $3.15 to $5.75 in the past 52 weeks.

On Tuesday, Genprex had said it entered into an exclusive license agreement with the University of Pittsburgh for a diabetes gene therapy that may have the potential to cure Type 1 and Type 2 diabetes, which together currently affect about 30.3 million people in the U.S, or 9 percent of the U.S. population. We had alerted the readers about the stock on Feb 11.

Under the agreement, the clinical-stage gene therapy company has licensed the patented diabetes gene therapy technology designed by researchers at the University of Pittsburgh. Genprex plans to pursue potential partnerships for the development of this therapy globally and in the U.S. The company will continue its focus on developing its immunogene therapies for cancer, including Oncoprex immunogene therapy, its lead drug candidate for non-small cell lung cancer, in parallel with development of the new diabetes gene therapy.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Federal Trade Commission (FTC) is in the process of sending out refund checks to consumers who were allegedly misled by Office Depot, Inc. and its software provider Support.com, Inc., into buying computer repair products and services. Out of $34 million, being the total amount of checks, Office Depot paid $25 million and Support.com paid $10 million as part of 2019 settlement. Gap Inc. partnered with fashion resale platform thredUP to facilitate the exchange of secondhand cloths. The retailer in a blog post said its customers can bring secondhand clothes in exchange for shopping credit that can be redeemed at Gap, Banana Republic, Athleta, or Janie and Jack. Customers who redeem their credits at Gap brands will receive an additional 15 percent payout bonus. Coca-Cola Co. (KO) on Friday reaffirmed its guidance for the full-year 2020 and provided an update on the expected impact from COVID-19 on first quarter 2020 results, ahead of its presentation at the Consumer Analyst Group of New York (CAGNY) Conference. For fiscal 2020, the company continues to project...
RELATED NEWS
Follow RTT
>